Acorda Therapeutics Inc logo

ACOR - Acorda Therapeutics Inc Share Price

$6.7 0.3  5.2%

Last Trade - 9:00pm

Micro Cap
Market Cap £37.2m
Enterprise Value £158.8m
Revenue £120.8m
Position in Universe 5176th / 6543
Unlock ACOR Revenue
Relative Strength (%)
1m +39.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
401.5 492.7 519.6 588.3 471.4 192.4 150.3 100.2 -13.7%
+31.6 -51.2
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AcordaTherapeutics Inc revenues decreased 19% to $114.8M. Netloss decreased 95% to $16.5M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsResearch and development - decrease of 65% to $17.3M(expense), Selling, general and administrative - Badecrease of 20% to $114.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ACOR Revenue Unlock ACOR Revenue

Net Income

ACOR Net Income Unlock ACOR Revenue

Normalised EPS

ACOR Normalised EPS Unlock ACOR Revenue

PE Ratio Range

ACOR PE Ratio Range Unlock ACOR Revenue

Dividend Yield Range

ACOR Dividend Yield Range Unlock ACOR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACOR EPS Forecasts Unlock ACOR Revenue
Profile Summary

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 17, 1995
Public Since February 10, 2006
No. of Shareholders: 17
No. of Employees: 344
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 7,993,733
Free Float (0.0%)
Eligible for
ACOR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ACOR
Upcoming Events for ACOR
Thursday 11th February, 2021 Estimate
Q4 2020 Acorda Therapeutics Inc Earnings Release
Monday 3rd May, 2021 Estimate
Q1 2021 Acorda Therapeutics Inc Earnings Release
Frequently Asked Questions for Acorda Therapeutics Inc
What is the Acorda Therapeutics Inc share price?

As of 9:00pm, shares in Acorda Therapeutics Inc are trading at $6.7, giving the company a market capitalisation of £37.2m. This share price information is delayed by 15 minutes.

How has the Acorda Therapeutics Inc share price performed this year?

Shares in Acorda Therapeutics Inc are currently trading at $6.7 and the price has moved by -50.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Acorda Therapeutics Inc price has moved by -56.61% over the past year.

What are the analyst and broker recommendations for Acorda Therapeutics Inc?

Of the analysts with advisory recommendations for Acorda Therapeutics Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Acorda Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Acorda Therapeutics Inc next release its financial results?

Acorda Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Acorda Therapeutics Inc dividend yield?

Acorda Therapeutics Inc does not currently pay a dividend.

Does Acorda Therapeutics Inc pay a dividend?

Acorda Therapeutics Inc does not currently pay a dividend.

When does Acorda Therapeutics Inc next pay dividends?

Acorda Therapeutics Inc does not currently pay a dividend.

How do I buy Acorda Therapeutics Inc shares?

To buy shares in Acorda Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Acorda Therapeutics Inc?

Shares in Acorda Therapeutics Inc are currently trading at $6.7, giving the company a market capitalisation of £37.2m.

Where are Acorda Therapeutics Inc shares listed? Where are Acorda Therapeutics Inc shares listed?

Here are the trading details for Acorda Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ACOR
What kind of share is Acorda Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Acorda Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Acorda Therapeutics Inc share price forecast 2021?

Shares in Acorda Therapeutics Inc are currently priced at $6.7. At that level they are trading at 0.261% discount to the analyst consensus target price of 0.00.

Analysts covering Acorda Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -8.608 for the next financial year.

How can I tell whether the Acorda Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acorda Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 23.14%. At the current price of $6.7, shares in Acorda Therapeutics Inc are trading at 40.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Acorda Therapeutics Inc PE Ratio?

The Acorda Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 5.58. The shares are currently trading at $6.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Acorda Therapeutics Inc?

Acorda Therapeutics Inc's management team is headed by:

Ron Cohen - CEO
David Lawrence - CAO
Sandra Panem - IND
Lorin Randall - IND
Barry Greene - IND
John Kelley - NEC
Lauren Sabella - OTH
Peder Jensen - IND
Burkhard Blank - OTH
Who are the major shareholders of Acorda Therapeutics Inc?

Here are the top five shareholders of Acorda Therapeutics Inc based on the size of their shareholding:

Symphony Asset Management LLC Investment Advisor/Hedge Fund
Percentage owned: 8.14% (772k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 6.75% (640k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.97% (377k shares)
Point72 Asset Management, L.P. Hedge Fund
Percentage owned: 3.51% (333k shares)
Acadian Asset Management LLC Investment Advisor/Hedge Fund
Percentage owned: 3.23% (306k shares)
Similar to ACOR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.